Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
Volume 0.47M
Average 0.96M
TYRA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Tyra Biosciences, Inc.NASDAQ: TYRA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $39.31M (cash outflow) rose 39.6% year over year, ahead of the +36.0% change in trailing-twelve-month net income. Sequentially, it rose 16.2% from the prior quarter. Over 3 fiscal years it compounded at +29.4% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$150.91M (+25.8%) for the fiscal year ending Dec 2026, a slowdown from the +38.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$39.31M+16.2% QoQ
- Last fiscal yearDec 2025
- -$119.95M+38.7% YoY
- LTMMar 2026
- -$131.11M+36.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +39.6% | +42.5% | +2.8 pp |
| 1 year | +38.7% | +25.8% | -12.9 pp |
| 3-year CAGR | +29.4% | +21.4% | -8.0 pp |
| 5-year CAGR | -16.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (119.95M) USD
- Year-over-year change
- -38.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (119.95M) | -38.7% |
| FY2024 | 2024-12-31 | (86.48M) | -25.1% |
| FY2023 | 2023-12-31 | (69.13M) | -25.0% |
| FY2022 | 2022-12-31 | (55.33M) | -110.4% |
| FY2021 | 2021-12-31 | (26.29M) | — |
Net Income vs competitors
How TYRA compares with its peers on the latest reported figures
- TYRA's LTM Mar 2026 net income of $131.11M is the 7th largest of the 11 companies compared; the peer median is $140.23M.
- Its year-over-year change of +36.0% is the 5th highest of 11, against a peer median of +28.2%.
- Over three fiscal years its annual growth of +29.4% compares with a peer median of +25.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $294.57M | +62.0% | +27.1% | 411.2% | |
| LTM Mar 2026 | $221.04M | +23.7% | — | — | |
| LTM Mar 2026 | $193.96M | +30.3% | +41.6% | 391.2% | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $157.32M | +70.4% | +53.9% | — |
| LTM Mar 2026 | $145.24M | +14.0% | +65.2% | — | |
| LTM Mar 2026 | $135.21M | +1.8% | +13.3% | — | |
| LTM Mar 2026 | $131.11M | +36.0% | +29.4% | — | |
| LTM Mar 2026 | $114.48M | +47.3% | +21.7% | 529.7% | |
| LTM Jun 2026 | $112.24M | +155.3% | +25.2% | 66.1% | |
| LTM Mar 2026 | $75.32M | -6.4% | -12.0% | 266.9% | |
| LTM Mar 2026 | $70.36M | +26.1% | -14.6% | 44.8% | |
| Peer median (excluding TYRA) | $140.23M | +28.2% | +25.2% | 329.0% | |
Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Depreciation & Amortization | 140K | 296K | 357K | 519K | 546K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.89M | 10.59M | 13.53M | 22.8M | 28.01M |
| Change in Working Capital | (481K) | (5.85M) | 6.36M | (729K) | (1.63M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.49M | 0 | 0 | 0 | 0 |
| Other Working Capital | (1.97M) | (5.85M) | 6.36M | (729K) | (1.63M) |
| Other Non-Cash Items | 3K | 3K | (1.25M) | (5.88M) | (2.12M) |
| Operating Cash Flow | (23.75M) | (50.29M) | (50.14M) | (69.77M) | (95.14M) |
| Capital Expenditures | (661K) | (559K) | (770K) | (664K) | (141K) |
| Acquisitions (Net) | 16K | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (143.84M) | (263.62M) | (101.25M) |
| Sales of Investments | 0 | 0 | 0 | 165.89M | 173.86M |
| Other Investing Activities | 16 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (645K) | (559K) | (144.61M) | (98.4M) | 72.46M |
| Debt Repayment | (9K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 181.22M | 632K | 1.54M | 200M | 8.1M |
| Common Stock Repurchased | 0 | 0 | 0 | (420K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 514K | 0 | 0 | 2.56M | 0 |
| Financing Cash Flow | 311.35M | 632K | 1.54M | 202.14M | 8.1M |
| Effect of Forex Changes | 0 | (757K) | 0 | 0 | 0 |
| Net Change in Cash | 286.96M | (50.97M) | (193.21M) | 33.96M | (14.58M) |
| Free Cash Flow | (24.41M) | (50.84M) | (50.91M) | (70.44M) | (95.28M) |
Tyra Biosciences, Inc.
NASDAQ:TYRA
Intrinsic Alpha fair value
Locked
Current Price
$19.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.